Work

Phase Ib study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab (bev) with or without paclitaxel.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.e13000

Authors: Jonathan Wade Goldman, Michael S. Gordon, Pamela N. Munster, Emily K. Bergsland, Amy Patricia Moore, Shuang Bai, Priti Hegde, Jill O. Fredrickson, Ilsung Chang, G. Scott Chandler, Roel Peter Funke, Ina Park Rhee, Daniel S. Chen, Lee S. Rosen

Institutions: University of California, Los Angeles, Pinnacle Oncology Hematology, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Genentech

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2243320223

Cites:

Cited by:

Related to: 10